PMID- 30056922
OWN - NLM
STAT- MEDLINE
DCOM- 20181026
LR  - 20211204
IS  - 1873-2623 (Electronic)
IS  - 0041-1345 (Linking)
VI  - 50
IP  - 6
DP  - 2018 Jul-Aug
TI  - Prevalence of Cervical Infection With Human Papillomavirus of High Oncogenic 
      Potential in Immunosuppressed Women on Renal Replacement Therapy With and Without 
      Mammalian Target of Rapamycin Inhibitors.
PG  - 1889-1891
LID - S0041-1345(18)30311-7 [pii]
LID - 10.1016/j.transproceed.2018.02.124 [doi]
AB  - BACKGROUND: Chronic immunosuppression constitutes a risk factor of human 
      papillomavirus (HPV) related cervical cancer development. Maintenance 
      immunosuppression with mammalian target of rapamycin (mTOR) inhibitors is 
      associated with decreased incidence of de novo malignancies in kidney graft 
      recipients. Recently published data suggest that mTOR inhibitors interfere with 
      viral replication. The aim of the study was to assess if there is a difference in 
      prevalence of HPV cervical infection in women on immunosuppressive regimens with 
      or without mTOR inhibitors. MATERIAL AND METHODS: Cervical swabs taken from 64 
      immunosuppressed women on renal replacement therapy were analyzed for the 
      presence of high-risk (HR) HPV DNA by means of an Amplicor HPV test and assessed 
      taking into account the recorded data on mTOR inhibitor use. RESULTS: The testing 
      revealed the presence of HR HPV DNA in none of the women that were treated with 
      mTOR inhibitors and in 21.4% of patients that were administered immunosuppressive 
      regimens without mTOR inhibitors (P = .08). Interestingly, 32% of women from the 
      mTOR(-) group in contrast to 12.5% in the mTOR(+) group declared having had more 
      than 2 lifetime sexual partners. CONCLUSIONS: Our results suggest that mTOR 
      inhibitors might constitute a promising therapy modification in women at risk of 
      HPV cervical malignancy development, but the effectiveness of such strategy 
      requires further studies.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Mazanowska, N
AU  - Mazanowska N
AD  - First Department of Obstetrics and Gynecology, Medical University of Warsaw, 
      Warsaw, Poland.
FAU - Szpotanska-Sikorska, M
AU  - Szpotanska-Sikorska M
AD  - First Department of Obstetrics and Gynecology, Medical University of Warsaw, 
      Warsaw, Poland. Electronic address: mszpotanska@wp.pl.
FAU - Madej, A
AU  - Madej A
AD  - First Department of Obstetrics and Gynecology, Medical University of Warsaw, 
      Warsaw, Poland.
FAU - Pazik, J
AU  - Pazik J
AD  - Department of Transplantation Medicine, Nephrology, and Internal Diseases, 
      Medical University of Warsaw, Warsaw, Poland.
FAU - Wielgos, M
AU  - Wielgos M
AD  - First Department of Obstetrics and Gynecology, Medical University of Warsaw, 
      Warsaw, Poland.
FAU - Pietrzak, B
AU  - Pietrzak B
AD  - First Department of Obstetrics and Gynecology, Medical University of Warsaw, 
      Warsaw, Poland.
LA  - eng
PT  - Journal Article
DEP - 20180314
PL  - United States
TA  - Transplant Proc
JT  - Transplantation proceedings
JID - 0243532
RN  - 0 (DNA, Viral)
RN  - 0 (Immunosuppressive Agents)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Adult
MH  - Cervix Uteri/*virology
MH  - DNA, Viral
MH  - Female
MH  - Humans
MH  - Immunosuppression Therapy/methods
MH  - Immunosuppressive Agents/*therapeutic use
MH  - Incidence
MH  - Middle Aged
MH  - Papillomaviridae/drug effects
MH  - Papillomavirus Infections/*epidemiology
MH  - Prevalence
MH  - *Renal Replacement Therapy
MH  - Risk Factors
MH  - Sirolimus/*therapeutic use
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors
MH  - Uterine Cervical Neoplasms/virology
EDAT- 2018/07/31 06:00
MHDA- 2018/10/27 06:00
CRDT- 2018/07/31 06:00
PHST- 2018/01/04 00:00 [received]
PHST- 2018/02/19 00:00 [accepted]
PHST- 2018/07/31 06:00 [entrez]
PHST- 2018/07/31 06:00 [pubmed]
PHST- 2018/10/27 06:00 [medline]
AID - S0041-1345(18)30311-7 [pii]
AID - 10.1016/j.transproceed.2018.02.124 [doi]
PST - ppublish
SO  - Transplant Proc. 2018 Jul-Aug;50(6):1889-1891. doi: 
      10.1016/j.transproceed.2018.02.124. Epub 2018 Mar 14.